In an industry where few independent preclinical CROs last more than a decade, TSRL’s 40-year milestone is a rare achievement. Founded in 1986 in Ann Arbor, Michigan with a vision to improve drug delivery for small molecules, the company has evolved into a science-first CRO known for its keen sense of strategy, high data quality, and lasting relationships across academia and industry.

TSRL, Inc. CEO, Elke Lipka, PhD, MBA, will be speaking at the in2being, LLC. MedTechCrossroads Women Who Innovate Series webinar subseries partnership with Michigan Economic Development Corporation.

When: Tuesday, November 12
8:00 am - 7:00 pm
Where: Kensington Court Hotel
3500 State St
Ann Arbor, Michigan 48108
United States

In July 2004, the Infectious Diseases Society of America (IDSA) released a report called "Bad Bugs, No Drugs." This report identified several species of antibiotic-resistant bacteria that were expected to play a lead role in the next global health crisis to come. The authors cited a high prevalence of drug-resistant infections--362,000 in the US in 2002--and lack of new antibiotics in development as warning signs. Twelve years have passed since the report published, and according to the CDC, >2 million people become infected and >23,000 die from drug-resistant infections every year. A 2009 paper by Boucher et al implicated six actors from their pathology, persistence, and presence in US hospitals: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa and Enterobacter. They termed them "ESKAPE" pathogens.